Vanda Pharmaceuticals seeks FDA nod for motion sickness drug
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a pharmaceutical company with a market capitalization of $256.56 million and impressive gross profit margins of 93.62%, disclosed through a social media post ...
Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now?
We recently compiled a list of the 10 Best Australian Stocks to Buy Now. In this article, we are going to take a look at ...
Exact Sciences: Liquid Biopsy Threat Is Solidifying
Discover why Exact Sciences, a leading oncology diagnostics company, may see growth in the cancer diagnostics market with its ...
FDA accepts Teva, Alvotech BLAs for Simponi biosimilars
Biologics License Applications for AVT05, their proposed biosimilar to the anti-inflammatory drugs Simponi and Simponi Aria. Review of the applications is expected to by completed in Q4 2025, ...
Triplex vaccine enters Phase 2 trial in stem cell donors
Fortress Biotech (NASDAQ:FBIO)'s Chairman and CEO, Dr. Lindsay (NYSE:LNN) A. Rosenwald, expressed optimism about the vaccine's role in preventing and treating CMV in the future. While analysts ...
DeepSeek is tanking AI stocks, except this one
DeepSeek, a Chinese startup, released an AI assistant last week trained at significantly reduced cost compared to U.S.
H.C. Wainwright maintains $40 target on GH Research stock
H.C. Wainwright reiterated a Buy rating on shares of GH Research PLC (NASDAQ:GHRS), with a price target of $40.00. Currently ...
Sage Therapeutics rejects Biogen bid, starts strategic review
Sage Therapeutics rejected a takeover offer from Biogen (BIIB) and said it started a process to review its strategic alternatives. Sage rose 5.6%. Sage's board will look at a range of opportunities, ...
Vertex stock price target cut to $533 by Piper Sandler
Piper Sandler made a slight adjustment to the price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), bringing it down to $533 from the previous target of $535, while maintaining an ...